ORPHA:502363
Squamous cell carcinoma of the oral cavity
Publications
46,883
99.2th percentile
Trials
139
Interventional, condition-specific
Researchers
1,378
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare head and neck tumor characterized by a firm infiltrative neoplasm with squamous differentiation, arising from the mucosal epithelium, and most commonly located in the tongue, floor of the mouth, or gingiva, but also the buccal mucosa or any other area of the oral cavity, depending on prevailing risk factors (such as smoking, alcohol consumption, and tobacco chewing). Patients present with a variably white, erythematous, mixed, nodular, or ulcerated lesion, which may cause discomfort, pain, or reduced mobility of the tongue. The tumor is aggressive with a propensity for local invasion and early lymph node metastasis.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0004958
- UMLS:C0585362
- NCIT:C4833
Additional Mondo synonyms (13)
mouth scc · mouth squamous cell carcinoma · oral cavity scc · oral cavity squamous cell cancer · oral cavity squamous cell carcinoma · scc of mouth · scc of oral cavity · scc of the mouth · scc of the oral cavity · squamous cell carcinoma of mouth · squamous cell carcinoma of oral cavity · squamous cell carcinoma of the mouth · squamous cell carcinoma of the oral cavity
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
46,883 matched papers (33,004 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelPresent
1 genotype model (Rattus norvegicus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
139 matched on ClinicalTrials.gov (32 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- HMT·RGD:68047·Rattus norvegicus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
69
Drugs / clinical candidates · MONDO_0004958
- ALDESLEUKIN·phase 3
- ATEZOLIZUMAB·phase 3
- AVELUMAB·phase 3
- CAMRELIZUMAB·phase 3
- CAPECITABINE·phase 3
- CISPLATIN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- DOCETAXEL·phase 3
- DURVALUMAB·phase 3
- DUSQUETIDE·phase 3
- FLUOROURACIL·phase 3
- INDOMETHACIN·phase 3
- LORNOXICAM·phase 3
- MELATONIN·phase 3
- METHOTREXATE·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
46,883
46,883 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
46,883 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
33,004 in the last 10 years · high confidence · 99.2th percentile (publications denominator)
Phrase hits: 46,883 · MeSH hits: 0
Who's working on it?
1,378
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Singh A8 papers · 2026
Department of Surgical Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
Papers in Europe PMC - 02Gupta A5 papers · 2026
Department of Clinical Oncology, Mount Vernon Cancer Centre, Greater London, United Kingdom.
Papers in Europe PMC - 03Huang SF5 papers · 2026
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC - 04Liao CT5 papers · 2026
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC. Electronic address: liaoct@cgmh.org.tw.
Papers in Europe PMC - 05Lin CY5 papers · 2026
Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC - 06Cheng NM4 papers · 2026
Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC - 07Hsieh CH4 papers · 2026
Department of Medical Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC - 08Kang CJ4 papers · 2026
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC - 09Kumar A4 papers · 2026
Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Papers in Europe PMC - 10Lee LY4 papers · 2026
Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
139
interventional trials for this specific condition
139 interventional trials matched this specific condition name; 32 currently recruiting in our sample.
Data as of 11 September 2026
139 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.9th percentile).
high confidence · 98.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
139 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05136196·RECRUITING·BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Not reviewed·Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8·Matched via name phrase
- NCT07667296·NOT YET RECRUITING·APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Cancer · Head and Neck (HNSCC) · Oropharyngeal · Oral Cavity·Matched via name phrase
- NCT06636734·RECRUITING·Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary · Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT04754321·RECRUITING·Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Not reviewed·Conditions: Head and Neck Carcinoma of Unknown Primary · Locally Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06980038·RECRUITING·Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma · Nasal Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07413627·NOT YET RECRUITING·A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers
Not reviewed·Conditions: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx·Matched via name phrase
- NCT05172245·RECRUITING·Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary · Locally Advanced Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06532279·RECRUITING·Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06097468·RECRUITING·Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Not reviewed·Conditions: Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT07335380·NOT YET RECRUITING·Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
Not reviewed·Conditions: Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT07121595·RECRUITING·Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Not reviewed·Conditions: Oral Cavity Squamous Cell Carcinoma · Stage I Lip and Oral Cavity Cancer AJCC v8 · Stage II Lip and Oral Cavity Cancer AJCC v8 · Stage III Lip and Oral Cavity Cancer AJCC v8·Matched via name phrase
- NCT06589804·RECRUITING·Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Not reviewed·Conditions: Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma · Metastatic Laryngeal Squamous Cell Carcinoma · Metastatic Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT04333537·RECRUITING·Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Not reviewed·Conditions: Buccal Mucosa Squamous Cell Carcinoma · Floor of Mouth Squamous Cell Carcinoma · Gingival Squamous Cell Carcinoma · Hard Palate Squamous Cell Carcinoma·Matched via name phrase
- NCT07484139·NOT YET RECRUITING·H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
Not reviewed·Conditions: Oral Cavity Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
Observational and natural-history studies
15 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT02507141·RECRUITING·Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
Not reviewed·Conditions: Head and Neck Cancer · Squamous Cell Carcinoma (SCC) of the Oral Cavity·Matched via name phrase
- NCT06380686·RECRUITING·Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Not reviewed·Conditions: Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT07529769·NOT YET RECRUITING·Artificial Intelligence for the Diagnosis of Oral Lesions
Not reviewed·Conditions: Oral Potentially Malignant Disorders · Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06947668·RECRUITING·Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Not reviewed·Conditions: Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Larynx Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 49 · after dedupe 49 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 49 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (49)
- ctis·2025-523617-29-01·Authorised·Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).
skipped — LLM skipped (--skip-llm)
- ctis·2024-517565-16-00·Authorised, ongoing·A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-520264-33-00·Authorised, ongoing·Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD-L1 positive HNSCC (CPS≥1)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521682-27-00·Not authorised·Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET/CT.
skipped — LLM skipped (--skip-llm)
- ctis·2025-520735-16-00·Cancelled·Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial (ECT-HN)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517480-23-00·Authorised, ongoing·Induction treatment of patients with head and neck squamous cell carcinoma using simultaneous chemotherapy and low-dose radiotherapy (iCHRTL)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511511-25-00·Cancelled·Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
skipped — LLM skipped (--skip-llm)
- ctis·2024-516536-10-00·Expired·Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC
in PD-L1 positive patients (CPS≥1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511477-29-00·Authorised, recruiting·AFAN trial. Phase Ib/II study to investigate the safety and efficacy of Afatinib when administered as therapy in Fanconi anemia patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx
skipped — LLM skipped (--skip-llm)
- ctis·2024-516189-12-00·Cancelled·Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer
skipped — LLM skipped (--skip-llm)
- ctis·2023-508561-33-00·Authorised, ongoing·A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15819396·Recruiting·A Phase I/IIa trial of KJ-103 in solid cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11941599·Recruiting·JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in LA-HNSCC
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14471479·Recruiting·How mouth bacteria affect radiation treatment for head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13376195·No longer recruiting·A study to evaluate the safety, processing by the body and response of the body to tenecteplase in adults with acute ischemic stroke
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63646763·No longer recruiting·A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66274524·No longer recruiting·Accelerating the development and implementation of DNA damage inhibitor and radiotherapy treatment (with or without immunotherapy) in head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17893221·No longer recruiting·Use of light waves to take cross-section pictures of the mouth (optical coherence tomography) in patients with an inflammatory condition that affects mucous membranes inside the mouth (oral lichen planus)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93840508·Stopped·Hyperbaric radiation sensitization of head and neck cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44750045·No longer recruiting·Sentinel node biopsy in head and neck cancer: development of a new technique
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98243550·No longer recruiting·Prophylactic swallowing exercise program in head and neck cancer patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89314418·Stopped·Cetuximab immunotherapy combination in head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17428671·Stopped·NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15120536·No longer recruiting·Swallowing impairment in oral cavity cancer patients treated with radiation therapy - current status, its impacts and effects of a swallowing exercise education program
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the oral cavity — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the oral cavity" OR "Squamous cell carcinoma of oral cavity" OR "mouth scc" OR "mouth squamous cell carcinoma" OR "oral cavity scc" OR "oral cavity squamous cell cancer" OR "oral cavity squamous cell carcinoma" OR "scc of mouth" OR "scc of the mouth" OR "scc of oral cavity" OR "scc of the oral cavity" OR "squamous cell carcinoma of mouth" OR "squamous cell carcinoma of the mouth"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the oral cavity" OR "Squamous cell carcinoma of oral cavity" OR "mouth scc" OR "mouth squamous cell carcinoma" OR "oral cavity scc" OR "oral cavity squamous cell cancer" OR "oral cavity squamous cell carcinoma" OR "scc of mouth" OR "scc of the mouth" OR "scc of oral cavity" OR "scc of the oral cavity" OR "squamous cell carcinoma of mouth" OR "squamous cell carcinoma of the mouth"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 139 interventional · 15 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:44:12.999Z
